C71T
CANCELLED SECTION 71
05/06/2026
Voltar para busca
Dado oficial do USPTO
T'SUMOYL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
30/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
3, 5
Data de depósito
18/09/2018
Data de registro
19/11/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/06/2026
Última transação
30/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
RUTLAND, BARBARA A
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Clinuvel (UK) Ltd
Representantes
Michelle P. Ciotola Cantor Colburn LLP
Classificação técnica
Classes Nice
Classe 3Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 3
Non-medicated skin care preparations; cosmetic preparations for skin care; cosmetic preparations for skin carebased on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic oils; cosmetic skin creams; skin care creamslotions and oils for cosmetic purposes; wrinkle removing skin care preparations; cosmetic sunscreen preparations; waterproof sunscreen; sunscreen preparations; sunscreen creams and lotions; cosmetics for protecting the skin from sunburn; sunblock lotions; cosmetic sun barriers; sun creams; cosmetic preparations for protecting the skin from the sun's rays; sun care lotions; cosmetic compounds for skin care after exposure to the sun's rays; after-sun milkscreamslotions and moisturizers; sun skin bronzers; sun-tanning preparations; cosmetics for tanning the skin including preparations for tanning without sunlightcontaining analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetics for tanning the skin including preparations for tanning without sunlightnot containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic self-tanning preparations; self -tanning creams and lotions for cosmetic purposes; suntan creamslotionsoils and gels; non-medicated skin rejuvenation preparationscreamslotionsmoisturizersgelsbalmsserumsoilstonerscleaners and peels; non-medicated skin rejuvenation productscreamslotionsmoisturizersgelsbalmsserumsoilstonerscleaners and peels with and without analogues of alpha-melanocyte stimulating hormone (alpha-MSH); non-medicated antiaging skincare preparations; antiaging creamslotionsmoisturizersgelsbalms and serums; skin cleansing creamslotionsmilksfoamsgels and masks for cosmetic purposes
Classe 5
Pharmaceuticals for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceuticals for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical drugs for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceutical drugs for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical preparations for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceutical preparations for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun tanning preparations for pharmaceutical purposescontaining analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun tanning preparations for pharmaceutical purposesnot containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; medicated dermatological preparations; dermatological pharmaceutical substances; dermatological pharmaceutical products; medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; chemical and biological preparationssubstancesreagents and compounds for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin woundsall used for the delivery and storage of pharmaceuticals containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
19/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
27/03/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/03/2020
FIMP
FINAL DISPOSITION PROCESSED
11/03/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/02/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
19/11/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/09/2019
PUBO
PUBLISHED FOR OPPOSITION
03/09/2019
GPNX
NOTIFICATION PROCESSED BY IB
30/08/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/08/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/08/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/08/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/07/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/07/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/07/2019
ALIE
ASSIGNED TO LIE
16/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/07/2019
RFNT
REFUSAL PROCESSED BY IB
02/02/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/01/2019
RFRR
REFUSAL PROCESSED BY MPU
17/01/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/01/2019
CNRT
NON-FINAL ACTION WRITTEN
04/01/2019
DOCK
ASSIGNED TO EXAMINER
28/12/2018
MAFR
APPLICATION FILING RECEIPT MAILED
30/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/11/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
22/11/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace T'SUMOYL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.